临床试验 以下为当前的临床试验。535 研究 肿瘤科(内科) (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas Rochester, Minn., Jacksonville, Fla. This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Rochester, Minn. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Rochester, Minn. This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Rochester, Minn. The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the response rate of the combination of Pemetrexed and Pembrolizumab in patients with recurrent or metastatic salivary gland cancer (R/M SGC). A Study of DNA/RNA Sequencing Results on the Clinical Management of Patients with Advanced Malignancies Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to assess practice patterns and changes in treatment recommendations based on the results obtained from a clinically available, comprehensive next generation DNA/RNA sequencing assay. A database of paired clinical and sequencing data will also be established for future research. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Rochester, Minn. The purpose of this study is to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Rochester, Minn., Scottsdale/Phoenix, Ariz. In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy. Treating Breast Cancer Patients Undergoing Trastuzumab Treatment with Carvedilol to Reduce Incidence of Heart Failure Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to evaluate different strategies of cardiovascular therapy with Carvedilol, aiming to reduce the incidence of left ventricular ejection fraction (LVEF) decline and heart failure (HF) in patients undergoing curative intent Trastuzumab for breast cancer. . The Impact of a Geriatric Assessment in Elderly Patients with Multiple Myeloma Rochester, Minn. The purpose of this study is to evaluate the association between a baseline comprehensive geriatric assessment (cGA) and chemotherapy toxicity in the first 4 months of treatment measured by treatment-related adverse events, patient-reported outcomes (PROs), and treatment discontinuation in older patients (≥ 65 years) with multiple myeloma (MM). Multiple myeloma (MM) is a blood cancer that affects a type of white cell called plasma cell. It mainly affects older individuals and has an average age at diagnosis of 69 years. Pagination 临床研究 PrevPrevious Page Go to page 4343 Go to page 4444 Go to page 4545 Go to page 4646 Go to page 4747 NextNext Page 申请预约 专长与排名研究 May 09, 2023 在《美国新闻与世界报道》2023-2024 年度全美最佳癌症医院评选中,妙佑医疗国际明尼苏达州罗切斯特院区、妙佑医疗国际佛罗里达州杰克逊维尔院区和妙佑医疗国际亚利桑那州凤凰城/斯科茨代尔院区均名列前茅。 了解更多关于这一最高荣誉的信息 肿瘤科(内科)科室首页部分概述主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 研究完全以患者为中心。 请参见副本 供视频使用 研究完全以患者为中心。 [音乐播放] 妙佑医疗国际神经学教授 Joseph Sirven 医学博士:妙佑医疗的使命以患者为中心。患者第一。我们的使命和研究是为了更好地帮助患者,提供以患者为中心的护理。在很多方面,这是一个循环。这个过程可能很简单,就是先在实验室里出现一个想法,然后带到病床旁加以实施,如果一切顺利,对患者有所助益, 就形成标准。我认为这就是妙佑医疗国际研究方法的一个独特之处,而这种以患者为中心的方式,也是妙佑医疗在众多医疗机构中脱颖而出的原因之一。 部分预约门诊概述主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 ORG-20180179 医学科室与中心 肿瘤科(内科)